- Home
- BNR vs KZIA Comparison
BNR vs KZIA Comparison
Compare BNR & KZIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BNR | KZIA |
|---|---|---|
| Founded | 2014 | 1994 |
| Country | China | Australia |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 169.9M | 186.7M |
| IPO Year | 2019 | 2002 |
Fundamental Metrics
Financial Performance| Metric | BNR | KZIA |
|---|---|---|
| Price | $12.53 | $7.93 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $28.33 |
| AVG Volume (30 Days) | 28.2K | ★ 252.2K |
| Earning Date | 11-19-2026 | 11-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $101.46 | N/A |
| Revenue Next Year | $14.81 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $6.79 | $4.86 |
| 52 Week High | $41.72 | $17.40 |
Technical Indicators
Market Signals| Indicator | BNR | KZIA |
|---|---|---|
| Relative Strength Index (RSI) | 38.66 | 32.92 |
| Support Level | $8.91 | $6.82 |
| Resistance Level | $12.89 | $8.18 |
| Average True Range (ATR) | 1.50 | 0.63 |
| MACD | -0.63 | -0.09 |
| Stochastic Oscillator | 7.29 | 29.73 |
Price Performance
Historical ComparisonAbout BNR Burning Rock Biotech Limited
Burning Rock Biotech Ltd is a cancer diagnostics company. The Group provides pharma research and development services, mainly cancer therapy selection tests services, companion diagnostics development services, and other service agreements with the combination of various customized tests services and analytical validation services, to pharmaceutical companies for developing new drugs for targeted therapies, immunotherapies on various types of cancers, and to hospitals for their studies on cancer diagnosis & treatment. It had three operating segments, including the Central laboratory business, the In-hospital business, & Pharma research & development services. It generates the majority of its revenue from the Central laboratory business. Its products are Pan-HEME, OncoScreen-WES, & others.
About KZIA Kazia Therapeutics Limited
Kazia Therapeutics Ltd is a biotechnology company focused on pharmaceutical drug development in oncology. The company has a portfolio of development candidates across various technologies targeting multiple cancer indications. Its primary program is Paxalisib, an investigational brain-penetrant inhibitor of the PI3K/Akt/mTOR pathway, designed for the treatment of brain cancer. The company develops targeted therapies aimed at addressing medical needs in oncology. The company operates in Australia and the United States.